Bullish Moving Averages
13
Bearish Moving Averages
3
Back Stocks profile
Stock analysis tool for investors
Performance
Open Price
31.50Prev. Close
31.3000Volume
2444.00Value
75495.16Fundamentals
Market Cap
11.60
Price to Earnings
-2.00
Price to Book Value
110.00
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM
11.05
Net Profit TTM
-5.75
Cash From Operating Activity
-0.20
Return on Equity %
-5458.99
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
94.7
Week
91.5
Month
86.7
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
31.29
PIVOT
First Resistance
32.59
Second Resistance
34.28
Third Resistance
35.58
First Support
29.60
Second Support
28.30
Third Support
26.61
Relative Strength Index
52.32
Money Flow Index
66.74
MACD
0.02
MACD Signal
-0.13
Average True Range
2.4
Average Directional Index
14.75
Rate of Change (21)
2.97
Rate of Change (125)
-3.47
Commodity Channel Index
141.4
Williams %R
-58.6
BETA
1 Month
0.01
3 Month
-0.38
1 Year
-0.18
3 Year
0.01
PRICE CHANGE ANALYSIS
↑ 2.45%
1 Week
Low
High
29
33.99
↓ -1.31%
1 Month
Low
High
28.62
33.99
↑ 1.44%
3 Months
Low
High
25.03
37.9
↓ -6.11%
6 Months
Low
High
24.18
37.9
↑ 3.31%
1 Year
Low
High
24.18
37.9
06 Jul 2024
Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
certificate received from RTA under regulation 74(5) of Depositary and Participants Regulations, 2018 for the quarter ended on 30th June, 2024
28 Jun 2024
Parmax Pharma Ltd - 540359 - Closure of Trading Window
In pursuant to company''s code of practices and procedure and code of conduct; to regulate, monitor and report trading in securities and SEBI (PIT)Regulations, 2015, Trading Window for dealing in securities of the company for designated persons will remain closed with immediate effect till 48 hours after declaration of the financial results for the quarter ending on 30th June, 2024.
08 Jun 2024
Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Revised Outcome
With reference to your e-mail/ Query raised dated 5th June, 2024 regarding Non- submission of statement as mentioned below: Non Submission: 1. Standalone Results - Declaration or Statement of Impact of Audit Qualifications not submitted in Pdf Mode for Year Ended - March 2024 We hereby clarify you that the declaration for Impact of audit qualifications was inadvertently omitted from the recently uploaded financial results . Therefore, we are hereby enclosing the revised Financial Results of year ended 31st March, 2024 along with the declaration of Impact of Audit Qualifications. The same has been approved by the board in the board meeting held on 30th May, 2024.
31 May 2024
Parmax Pharma Ltd - 540359 - Certificate For Non Applicability Of The Provision Of Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Year Ended On 31St March, 2024.
As per Regulation 23(9) of SEBI (LODR) Regulations, 2015, the provisions mentioned under the same regulations shall not be applicable to our company as the paid up share capital is less than 10 crore and net worth of the company is less than 25 crore as on 31/03/2024. hence, the company is not required to submit disclosure of related party transactions for the year ended on 31st March, 2024.
30 May 2024
Parmax Pharma Ltd - 540359 - The Board Of Directors Of The Company Has, At Its Meeting Held Today, Inter Alia, Considered And Approved The Audited Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024
the board of directors of the company at its meeting held today has considered and approved the audited financial results of the company for the quarter and the year ended on 31st march, 2024 along with statement of asset and liability, cash flow and the audit report.
30 May 2024
Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Board Of Directors Of The Company Has, Onsidered And Approved The Audited Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024
the Board of Directors of the company has, at its meeting held today, inter alia, considered and approved the Audited financial results of the company for the quarter and year ended on March 31, 2024 along with statement of assets and liabilities as on that date, statement of cash flow, statement on impact of Audit Qualifications on standalone financial results along with auditor's report issued by B. A. SHAH S. R. MEHTA & CO., Statutory auditors of the company.
27 May 2024
Parmax Pharma Ltd - 540359 - Update on board meeting
The Board Meeting to be held on 28/05/2024 has been revised to 30/05/2024 The Board Meeting to be held on 28/05/2024 has been revised to 30/05/2024
20 May 2024
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for To Approve The Audited Financial Statements For The Quarter And Year Ended On 31.03.2024.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 ,inter alia, to consider and approve 1. to approve financial results for the quarterand year ended on 31.03.2024. 2. other matters with permission of the chairman
02 May 2024
Parmax Pharma Ltd - 540359 - Appointment of Company Secretary and Compliance Officer
Meeting of the Board of Directors of Parmax Pharma Limited held on 2nd May, 2024 at 5.00 pm at registered office of the company and board has approved the appointment of Ms. Bhakti Aghera as a company secretary cum compliance officer of the company w.e.f. 02/05/2024.
29 Apr 2024
Parmax Pharma Ltd - 540359 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyParmax Pharma Ltd 2CIN NO.L24231GJ1994PLC023504 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.33 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: UMANG GOSALIA Designation: MANAGING DIRECTOR EmailId: [email protected] Name of the Chief Financial Officer: KEYUR VORA Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
